Skip to Main Content
Table 2

Efficacy data from the phase III trial

Efficacy variableRandomized and treated patients
Fully supplemented patients
Pemetrexed + cisplatin (n = 226)Cisplatin (n = 222)Pemetrexed + cisplatin (n = 168)Cisplatin (n = 163)
Median overall survival, mo (95% confidence interval) 12.1 (10.0-14.4) 9.3 (7.8-10.7) 13.3 (11.4-14.9) 10.0 (8.4-11.9) 
Hazard ratio (95% confidence interval) 0.77 (0.61-0.96)  0.76 (0.57-1.0)  
P (log-rank)* 0.021  0.051  
% Alive 35.8 28.4 43.5 36.8 
Efficacy variableRandomized and treated patients
Fully supplemented patients
Pemetrexed + cisplatin (n = 226)Cisplatin (n = 222)Pemetrexed + cisplatin (n = 168)Cisplatin (n = 163)
Median overall survival, mo (95% confidence interval) 12.1 (10.0-14.4) 9.3 (7.8-10.7) 13.3 (11.4-14.9) 10.0 (8.4-11.9) 
Hazard ratio (95% confidence interval) 0.77 (0.61-0.96)  0.76 (0.57-1.0)  
P (log-rank)* 0.021  0.051  
% Alive 35.8 28.4 43.5 36.8 
*

P is based on the two-sided log-rank test.

Close Modal

or Create an Account

Close Modal
Close Modal